Last reviewed · How we verify
DECA
At a glance
| Generic name | DECA |
|---|---|
| Also known as | Dexamethasone (D), Etoposide (E), Cytarabine (A), Cisplatin (C) |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Antiseptic preparation
Common side effects
- Parkinsonism
- Oculogyric crisis
- Sedation
- Somnolence
- Dyskinesia
- Dystonia
- Cogwheel rigidity
- Muscle rigidity
- Hypertonia
- Masked facies
- Constipation
- Dry mouth
Serious adverse events
- Neuroleptic malignant syndrome
- Tardive dyskinesia
- Sudden death
- Ventricular fibrillation
- Torsade de pointes
- Ventricular tachycardia
- Acute hepatic failure
- Agranulocytosis
- Anaphylactic reaction
- Pancytopenia
Key clinical trials
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (PHASE1)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DECA CI brief — competitive landscape report
- DECA updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI